S. KREPS: Open Payments
NPI 1689728321 · PITTSBURGH, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$854 in 24 payments from 8 companies in 2025. Trend: 2023 $1,232 · 2024 $1,229 · 2025 $854
Food & beverage: $854
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 12 | $290 |
| Alkermes, Inc. | 2 | $145 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $122 |
| Teva Pharmaceuticals USA, Inc. | 1 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $102 |
| Neurocrine BioSciences, Inc. | 2 | $40 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
Products named: VRAYLAR, LYBALVI, CAPLYTA, REXULTI, INGREZZA, TRINTELLIX, ARISTADA.
Industry payments across PA — which companies pay providers there.
